ClinicalTrials.gg
RecruitingNCT06377254CHAINUpdated Dec 4, 2025

Multi-organ Responses to CHronic Physical Activity and INactivity

An interventional study of Decreased Physical Activity and Increased Physical activity in Sedentary Behavior, Metabolic Syndrome and Age-related Cognitive Decline, sponsored by University of Nottingham. Recruiting at 1 site in United Kingdom. Open to participants aged 50 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-04.

Sponsored by University of Nottingham · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
50 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 52 studies in Sedentary Behavior with a site in United Kingdom — 10 open to participants now, 10 under way, none of them phase 3. Sedentary Behavior · United Kingdom.

Planned enrollment
18th of 48
40 · median 34
Started
2024
with 5 others
No phase
47 of 52
9 open now
Registered
45th of 52
by date
Lead sponsor
4 of 52
University of Nottingham

Among the 52 studies in Sedentary Behavior with a site in United Kingdom, this one is the 18th largest by planned enrollment of the 48 interventional ones that give a count, is one of 6 that started in 2024, is one of 47 with no phase, and was the 45th registered.

Sedentary Behavior

1,276 studies on the registry are indexed under Sedentary Behavior; 292 are open to participants now.

Browse Sedentary Behavior studies →

Open to participants now

10 of the 52 studies in Sedentary Behavior with a site in United Kingdom are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 184 Sedentary Behavior studies recruiting now, 77 (42%) set no upper age limit and 82 (45%) stop at 75 or younger; 30 take children under 18; 97 take healthy volunteers.

This study: 50 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Sedentary Behavior with a site in United Kingdom, or all of them as a file.
02

Study summary

Life expectancy has been increasing for the last 150 years, but the maintenance of health has not kept pace with increased lifespan, and on average, UK adults spend the last decade of life in poor-health, with major consequences for society and the individual.

Persistent physical inactivity is thought to be a key contributing factor to the risk of poor health and functional decline occurring in middle-aged and older adults. It is therefore concerning that most middle-aged adults spend >8hrs/day being sedentary, with average step count of 3000-4000 steps/day.

To be able to holistically assess the effectiveness of future strategies to address age-related decline in health, and devise public health messages to help individuals reach older age in better health, it is essential that the complex physiological effects that activity and inactivity have across biological systems are characterised.

The goal of this intervention study is to compare the impact of physical activity and inactivity on body functioning. Twenty moderately active participants will decrease their physical activity for three months to match the average amount carried out by middle-aged people in the UK. They will then undertake 3-months of reconditioning training to restore their fitness. In addition, twenty sedentary participants will increase their physical activity to UK recommended levels for six months.

Before and at points during the intervention period, participants will be asked to make some measurements at home and attend the University of Nottingham to have multiple assessments made. These include;

  • fitness, muscle strength and function tests,
  • completion of questionnaires and computer-based brain puzzles
  • having muscle and fat tissue biopsies and blood samples taken.
  • The study also involves having MRI scans.

This 5-year study will commence in January 2024, with participant recruitment starting in March 2024 and finishing in May 2027.

Read the detailed description

This is a parallel design study comparing the impact of physical activity and inactivity on the way the body functions, to understand the mechanisms (including the inter-relationship between tissues and organs) by which lifestyle behaviours may effect health and wellbeing in later life. In particular, the mechanisms by which inactivity results in long term poor health is not well understood, and has rarely been studied in an integrated way in people. However, initial research indicates that the physiology of being inactive is not simply the reverse of being active. To enable effective treatments and public health advice to be devised so that more adults reach old age in better health, and maintain a good quality of life for a greater proportion of their older age, it is important that the impact of physical inactivity on the way the body functions is better understood. Therefore, twenty participants who are moderately, but not highly active will be asked to decrease their physical activity for three months to match the average exercise levels of middle-aged people in the United Kingdom (UK). This will require them to increase their daily sitting time to 7 hours a day and reduce their step count to \<4500 steps per day. At the end of the 3-months they will undertake 3-months of supervised reconditioning training by attending the Medical School at Queen's Medical Centre, Nottingham, three times a week.

In addition, twenty participants who currently have low physical activity levels will be asked to increase their physical activity to UK recommended levels by attending the Medical School at Queen's Medical Centre, Nottingham, three times a week for six months to undertake a supervised exercise program.

Before and during the 6-month period (at weeks 6, 12, 18 and 24) participants will be asked to make some measurements at home (physical activity levels, dietary intake) and attend the University of Nottingham over 4 days to have multiple assessments made. These include: height; weight; body composition (body fat and lean tissue); blood pressure; fitness, muscle strength and function; sleep quality, quality of life and wellbeing (questionnaires). The rate of muscle protein breakdown and muscle protein synthesis, blood sugar regulation, and biochemistry of the blood, fat tissue and muscles will be assessed, and to enable this muscle and fat tissue biopsies will be collected and blood samples taken. The study also involves having MRI scans to study the structure and function of the brain and heart, and to determine liver and muscle fat content.

03

Conditions studied

  • Sedentary Behavior
  • Metabolic Syndrome
  • Age-related Cognitive Decline
  • Age-Related Sarcopenia

Keywords

  • Physical activity
  • middle-age
  • Physical inactivity
  • overweight
  • lifestyle
04

Who can participate

Ages eligible
50 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Group 1 ('non-sedentary') self-reporting \<6 sedentary hrs/day, not actively involved in exercise training or a regular physical activity regimen (>8,000 steps/day).
  • Group 2 ('sedentary') self-reporting ≥8 waking hrs/day in sedentary activities and/or ≤5,000 steps/day.
  • Aged 50-65y.
  • Overweight ( 25-35 kg/m2).
  • Waist circumference ≥94cm (males) and ≥80cm (females).
  • Willing to alter physical activity levels as instructed for 6 months
  • Without neurological or psychiatric diseases, motor or cognitive restrictions
  • Ability to give

Exclusion criteria

Exclusion Criteria:

  • Regular medication use that could interfere with measures
  • A history, or evidence, of chronic cardiovascular, metabolic, musculoskeletal, renal or respiratory diseases.
  • Experiencing 'long-COVID', inflammatory bowel disease or .
  • Uncontrolled hypertension. Stage 1 hypertension (BP ≤160/100mmHg) with no other signs of cardiovascular disease, and blood pressure (BP) managed by routine medication will not be an exclusion.
  • People employed in jobs that would preclude reducing step count and night-shift workers.
  • Females who are pre/peri-menopausal, (due to effect of oestrogen fluctuations on primary outcomes and the longitudinal study design), but individuals stable on hormone replacement therapy are eligible.
  • for MRI.
  • Allergy or sensitivity to local anaesthesia, or dressing adhesive
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Inactivity

    Participants in this group will reduce their physical activity (increase sitting time to 7hrs/day and decrease step count to \<4500/day) for 3 months, then increase their activity for 3 months, through attending 3x 45 min supervised exercise sessions/week.

    Behavioral: Decreased Physical Activity

  • Experimental
    Activity

    Participants in this group will have moderate intensity physical activity levels increased for 6 months, through attending 3x 45 min supervised exercise sessions/week.

    Behavioral: Increased Physical activity

Interventions

  • BehavioralDecreased Physical Activity

    Physical activity levels will be decreased

  • BehavioralIncreased Physical activity

    Physical activity levels will be increased

06

What researchers measure

Primary outcomes

  1. Change in Cardiorespiratory fitness (VO2 max)

    change in maximal oxygen uptake (continuous incremental bicycle ergometer exercise test with on-line gas analysis) measured every 6 weeks

    Time frame: 12 weeks

Secondary outcomes

  1. Change in Isometric leg strength

    Change in Isometric leg strength measured every 6 weeks using CYBEX dynamometer

    Time frame: 24 weeks

  2. Change in time to leg fatigue

    Change in time taken to induce muscle fatigue measured every 6 weeks using isokinetic knee extensions on a CYBEX dynamometer

    Time frame: 24 weeks

  3. Change in incremental area under the curve (iAUC) for blood glucose concentration

    Change in 180 minute blood glucose concentration incremental area under the curve measured every 6 weeks during an oral glucose tolerance test.

    Time frame: 24 weeks

  4. Change in iAUC for serum insulin concentration

    Change in 180-minute serum insulin concentration incremental area under the curve measured every 6 weeks during an oral glucose tolerance test

    Time frame: 24 weeks

  5. Change in fasting glucose oxidation rate

    Change in glucose oxidation rate (when fasted), measured every 6 weeks using ventilated hood indirect calorimetry

    Time frame: 24 weeks

  6. Change in 'fed' glucose oxidation rate

    Change in glucose oxidation rate (in the insulin-stimulated 'fed' state), measured every 6 weeks using ventilated hood indirect calorimetry during an oral glucose tolerance test

    Time frame: 24 weeks

  7. Change in Short Form Health Survey (SF36) Questionnaire aggregated normalised 'physical' score

    Change in 'SF36' Questionnaire aggregated 'physical' score (normalised to UK population) calculated according to standard procedures (min 0, max 100), with higher score indicating better physical wellbeing measured every 6 weeks

    Time frame: 24 weeks

  8. Change in Short Form Health Survey (SF36) Questionnaire aggregated and normalised 'mental' score

    Change in 'SF36' Questionnaire aggregated 'mental' score (normalised to UK population) calculated according to standard procedures (min 0, max 100), with higher score indicating better mental wellbeing, measured every 6 weeks

    Time frame: 24 weeks

  9. Change in World Health Organisation Quality of Life (WHOQoL) score

    Change in World Health Organisation Quality of Life Score (measured using the WHOQoL-Bref questionnaire every 6 weeks), (min score 0, max 100), with higher score indicating a better state of health.

    Time frame: 24 weeks

  10. Change in Pittsburgh Sleep Quality Index (PSQI)

    Change in PSQI score (min score 0, max 21), measured every 6 weeks, with higher score indicating poorer sleep quality

    Time frame: 24 weeks

  11. Change in Stroop test; % Accuracy

    Change in the percentage of accurate responses, measured every 6 weeks, with higher score indicating better cognitive performance. Minimum value 0%, maximum value 100%

    Time frame: 24 weeks

  12. Change in Stroop test; reaction time

    Change in the reaction time for responses, measured every 6 weeks, with higher score indicating slower cognitive performance. No minimum or maximum value defined.

    Time frame: 24 weeks

  13. Change in four-choice reaction time test; % Accuracy

    Change in the percentage of accurate responses, measured every 6 weeks, with higher score indicating better cognitive performance. Minimum value 0%, maximum value 100%

    Time frame: 24 weeks

  14. Change in four-choice reaction time test; reaction time

    Change in the reaction time for responses, measured every 6 weeks, with higher score indicating slower cognitive performance. No minimum or maximum value defined.

    Time frame: 24 weeks

  15. Change in card sort test; % Accuracy

    Change in the percentage of accurate responses, measured every 6 weeks, with higher score indicating better cognitive performance. Minimum value 0%, maximum value 100%

    Time frame: 24 weeks

  16. Change in card sort test; reaction time

    Change in the reaction time for responses, measured every 6 weeks, with higher score indicating slower cognitive performance. No minimum or maximum value defined.

    Time frame: 24 weeks

  17. Change in Logical reasoning test; % accuracy

    Change in the accuracy of responses, measured every 6 weeks, with higher score indicating better cognitive performance. Minimum value 0%, maximum value 100%

    Time frame: 24 weeks

  18. Change in Logical reasoning test; reaction time

    Change in the reaction time for responses, measured every 6 weeks, with higher score indicating slower cognitive performance. No minimum or maximum value defined.

    Time frame: 24 weeks

  19. Change in serial subtractions test; number of responses in 2 minutes

    Change in the number of responses, measured every 6 weeks, with higher score indicating better cognitive performance. minimum number is 0, maximum number is variable dependent on starting value (800-999; randomly selected by computer program) and speed of response.

    Time frame: 24 weeks

  20. Change in Corsi blocks test; score

    Change in the test score, measured every 6 weeks, with higher score indicating better cognitive performance.Minimum score is 0 and maximum is 15.

    Time frame: 24 weeks

  21. Change in Muscle protein synthesis rate

    Muscle synthesis protein rate calculated from deuterium incorporation into muscle tissue

    Time frame: 24 weeks

  22. Change in Muscle protein breakdown rate

    Muscle protein breakdown rate calculated every 6 weeks using 3-methylhistidine tracer

    Time frame: 24 weeks

  23. Change in whole body fat volumes

    Change in the amount of fat within the body, measured every 6 weeks using magnetic resonance imaging (MRI)

    Time frame: 24 weeks

  24. Change in liver fat volumes

    Change in the amount of fat within the liver, measured every 6 weeks using magnetic resonance imaging (MRI)

    Time frame: 24 weeks

  25. Change in thigh muscle fat volumes

    Change in the amount of fat within the vastus lateralis thigh muscle, measured every 6 weeks using magnetic resonance imaging (MRI)

    Time frame: 24 weeks

  26. Change in whole body muscle volumes

    Change in the amount of muscle within the body, measured every 6 weeks using magnetic resonance imaging (MRI)

    Time frame: 24 weeks

  27. Change in muscle phosphocreatine synthesis rate

    Change in the rate of phosphocreatine synthesis, measured every 6 weeks using magnetic resonance spectroscopy

    Time frame: 24 weeks

  28. Change in cerebral volume

    Change in the volume of brain tissue, measured every 6 weeks using magnetic resonance imaging (MRI)

    Time frame: 24 weeks

  29. Change in cortical thickness

    Change in the thickness of the brain cortex, measured every 6 weeks using magnetic resonance imaging (MRI)

    Time frame: 24 weeks

  30. Change in plasma metabolome

    change in untargeted plasma metabolome profile measured every 6 weeks

    Time frame: 24 weeks

Other outcomes

  1. Fasting blood lipid concentration

    concentration of lipid within the blood

    Time frame: pre-intervention

  2. Fasting blood lipid concentration

    concentration of lipid within the blood

    Time frame: 6 weeks

  3. Fasting blood lipid concentration

    concentration of lipid within the blood

    Time frame: 12 weeks

  4. Fasting blood lipid concentration

    concentration of lipid within the blood

    Time frame: 18 weeks

  5. Fasting blood lipid concentration

    concentration of lipid within the blood

    Time frame: 24 weeks

  6. liver function test: alanine transaminase (ALT)

    concentration of ALT measured on blood sample

    Time frame: pre-intervention

  7. liver function test: alanine transaminase (ALT)

    concentration of ALT measured on blood sample

    Time frame: 6 weeks

  8. liver function test: alanine transaminase (ALT)

    concentration of ALT measured on blood sample

    Time frame: 12 weeks

  9. liver function test: alanine transaminase (ALT)

    concentration of ALT measured on blood sample

    Time frame: 18 weeks

  10. liver function test: alanine transaminase (ALT)

    concentration of ALT measured on blood sample

    Time frame: 24 weeks

  11. liver function test: aspartate aminotransferase (AST)

    concentration of AST measured on blood sample

    Time frame: pre-intervention

  12. liver function test: aspartate aminotransferase (AST)

    concentration of AST measured on blood sample

    Time frame: 6 weeks

  13. liver function test: aspartate aminotransferase (AST)

    concentration of AST measured on blood sample

    Time frame: 12 weeks

  14. liver function test: aspartate aminotransferase (AST)

    concentration of AST measured on blood sample

    Time frame: 18 weeks

  15. liver function test: aspartate aminotransferase (AST)

    concentration of AST measured on blood sample

    Time frame: 24 weeks

  16. liver function test: Bilirubin

    concentration of bilirubin measured on blood sample

    Time frame: pre-intervention

  17. liver function test: Bilirubin

    concentration of bilirubin measured on blood sample

    Time frame: 6 weeks

  18. liver function test: Bilirubin

    concentration of bilirubin measured on blood sample

    Time frame: 12 weeks

  19. liver function test: Bilirubin

    concentration of bilirubin measured on blood sample

    Time frame: 18 weeks

  20. liver function test: Bilirubin

    concentration of bilirubin measured on blood sample

    Time frame: 24 weeks

  21. liver function test: Albumin

    concentration of albumin measured on blood sample

    Time frame: pre-intervention

  22. liver function test: Albumin

    concentration of albumin measured on blood sample

    Time frame: 6 weeks

  23. liver function test: Albumin

    concentration of albumin measured on blood sample

    Time frame: 12 weeks

  24. liver function test: Albumin

    concentration of albumin measured on blood sample

    Time frame: 18 weeks

  25. liver function test: Albumin

    concentration of albumin measured on blood sample

    Time frame: 24 weeks

  26. liver function test: Gamma glutamyl transferase (GGT)

    concentration of GGT measured on blood sample

    Time frame: pre-intervention

  27. liver function test: Gamma glutamyl transferase (GGT)

    concentration of GGT measured on blood sample

    Time frame: 6 weeks

  28. liver function test: Gamma glutamyl transferase (GGT)

    concentration of GGT measured on blood sample

    Time frame: 12 weeks

  29. liver function test: Gamma glutamyl transferase (GGT)

    concentration of GGT measured on blood sample

    Time frame: 18 weeks

  30. liver function test: Gamma glutamyl transferase (GGT)

    concentration of GGT measured on blood sample

    Time frame: 24 weeks

  31. Blood Haemoglobin concentration

    haemoglobin concentration measured on a blood sample

    Time frame: pre intervention

  32. Blood Haemoglobin concentration

    haemoglobin concentration measured on a blood sample

    Time frame: 6 weeks

  33. Blood Haemoglobin concentration

    haemoglobin concentration measured on a blood sample

    Time frame: 12 weeks

  34. Blood Haemoglobin concentration

    haemoglobin concentration measured on a blood sample

    Time frame: 18 weeks

  35. Blood Haemoglobin concentration

    haemoglobin concentration measured on a blood sample

    Time frame: 24 weeks

07

Study locations

1 of 1 sites recruiting
  • David Greenfield Human Physiology Unit
    Nottingham, Notts NG72UH, United Kingdom
    Recruiting
    • Sara Brown · Contactsara.brown@nottingham.ac.uk · +44(0)115 8230434
    • Joanne Mallinson, PhD · Contactjoanne.mallinson@nottingham.ac.uk · +44(0)1158230434
    • Paul Greenhaff, PhD · Principal investigator
    • Liz Simpson, PhD · Sub investigator
    • Joanne Mallinson, PhD · Sub investigator
    • Abhishek Sheth, MD · Sub investigator
    • Penny Gowland, PhD · Sub investigator
    • Sue Francis, PhD · Sub investigator
    • Rosemary Nicholls, PhD · Sub investigator
    • Sara Brown · Sub investigator
    • Donald Peden, PhD · Sub investigator
    • Alena Ponitzova · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes — Anonymised dataset will be made available to other researchers on request after study aims have been analysed and published. No patient identifiable data will be shared

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data will become available approximately 2 years after study completion and will be available for 20 years

Access criteria: Although parts of the data set generated from this project will be available on open access platforms to support publications, access to the full data repository and tissue archive will be through requests made to the Management Board. Access will be subject to ethical constraints, the preservation of intellectual property (IP), and written acknowledgement that it is a research collaboration, with data ownership residing with the original research teams. Data will be shared subject to a data transfer agreement and confirmation that deletion of the shared data set will occur once analysis has been completed.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Dec 2027, 45 months after the start.

Of 736 non-industry interventional studies with no phase under Sedentary Behavior, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 30. This study's planned 45 months is above that.

Counting every sponsor, half of 744 studies reached it within 14 months; a quarter within 6 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2024
First posted
Apr 22, 2024
StartActual
Mar 12, 2024
Primary completionEst.
Dec 17, 2027
CompletionEst.
Oct 31, 2028
Last update
Dec 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06377254
Collaborators
Biotechnology and Biological Sciences Research Council
Responsible party
Paul Greenhaff (Principal Investigator, University of Nottingham) — Principal investigator
First posted
Apr 22, 2024
Start date
Mar 12, 2024
Primary completion
Dec 17, 2027 (estimated)
Completion
Oct 31, 2028 (estimated)
Last update
Dec 4, 2025

Study contacts

Paul L Greenhaff (PI), PhD
Contact
paul.greenhaff@nottingham.ac.uk
+44 (0) 1158230133
Melanie Tooley (participant recruitment), BSc
Contact
melanie.marshall@nottingham.ac.uk
+44 (0) 115 9515151 ext. 19105
Paul L Greenhaff, PhD
principal investigator · University of Nottingham

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion